Search

Search results

173 results found

Small-Molecule Neutrophil Modulator ADS051 is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study.

Cheifetz, Adam S, Jessica R Allegretti, Megan Quintas, Bharat Dixit, Ronald Farquhar, Benjamin W Miller, Christopher K Murphy, Ellie Hershberger, Parviz Ghahramani, and A C Stevens. 2024. “Small-Molecule Neutrophil Modulator ADS051 Is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study.”. The American Journal of Gastroenterology 120 (7): 1585-92.

RETRACTED: Abou-Donia et al. Sex-Based Differences in Plasma Autoantibodies to Central Nervous System Proteins in Gulf War Veterans versus Healthy and Symptomatic Controls. Brain Sci. 2021, 11, 148.

Abou-Donia, Mohamed B, Maxine H Krengel, Elizabeth S Lapadula, Clara G Zundel, Jessica LeClair, Joseph Massaro, Emily Quinn, et al. 2024. “RETRACTED: Abou-Donia et Al. Sex-Based Differences in Plasma Autoantibodies to Central Nervous System Proteins in Gulf War Veterans versus Healthy and Symptomatic Controls. Brain Sci. 2021, 11, 148.”. Brain Sciences 14 (8).

When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease.

Systrom, Hannah K, Victoria Rai, Siddharth Singh, Leonard Baidoo, Adam S Cheifetz, Shane M Devlin, Krisztina B Gecse, et al. 2025. “When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease.”. The American Journal of Gastroenterology 120 (2): 420-30.

Tina Deyhim, M.D., M.P.H.

Tina Deyhim completed her medical education in Iran, where she developed a strong interest in inflammatory bowel disease (IBD) and conducted research in this area. In 2023, she joined the IBD group at Beth Israel Deaconess Medical Center (BIDMC), where she had the privilege of contributing to...